NADPH oxidase 2 activity in Parkinson’s disease

[1]  J. T. Greenamyre,et al.  LRRK2 and idiopathic Parkinson’s disease , 2022, Trends in Neurosciences.

[2]  E. K. Hoffman,et al.  Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay. , 2021, Bio-protocol.

[3]  Hope Johnson,et al.  Rac-dependent feedforward autoactivation of NOX2 leads to oxidative burst , 2021, The Journal of biological chemistry.

[4]  Simon C Watkins,et al.  α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo , 2020, Redox biology.

[5]  Sean M. Smith,et al.  LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease , 2019, Neurobiology of Disease.

[6]  G. Douglas,et al.  Nox2 contributes to age-related oxidative damage to neurons and the cerebral vasculature , 2019, The Journal of clinical investigation.

[7]  Daniel N. Meijles,et al.  NADPH oxidase 2 inhibitors CPP11G and CPP11H attenuate endothelial cell inflammation & vessel dysfunction and restore mouse hind-limb flow , 2019, Redox biology.

[8]  Shengdi Chen,et al.  Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease. , 2018, ACS chemical neuroscience.

[9]  A. Stepan,et al.  LRRK2 activation in idiopathic Parkinson’s disease , 2018, Science Translational Medicine.

[10]  A. Destée,et al.  NADPH oxidases in Parkinson’s disease: a systematic review , 2017, Molecular Neurodegeneration.

[11]  Caitlyn W. Barrett,et al.  α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease , 2016, Science Translational Medicine.

[12]  H. Schmidt,et al.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. , 2015, Antioxidants & redox signaling.

[13]  J. Blesa,et al.  Oxidative stress and Parkinson’s disease , 2015, Front. Neuroanat..

[14]  Victor Tapias,et al.  shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. , 2015, The Journal of clinical investigation.

[15]  L. Britto,et al.  NADPH Oxidase and the Degeneration of Dopaminergic Neurons in Parkinsonian Mice , 2013, Oxidative medicine and cellular longevity.

[16]  L. Sanders,et al.  Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. , 2013, Free radical biology & medicine.

[17]  P. Wipf,et al.  Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors. , 2013, MedChemComm.

[18]  T. Schäffer,et al.  Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity , 2013, Molecular and Cellular Neuroscience.

[19]  He-Jin Lee,et al.  Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein. , 2013, Antioxidants & redox signaling.

[20]  G. Csányi,et al.  NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS , 2012, Cellular and Molecular Life Sciences.

[21]  Dan Zhang,et al.  Rotenone activates phagocyte NADPH oxidase by binding to its membrane subunit gp91phox. , 2012, Free radical biology & medicine.

[22]  S. Dikalov.  Cross talk between mitochondria and NADPH oxidases. , 2011, Free radical biology & medicine.

[23]  L. Lopes,et al.  Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. , 2011, Free radical biology & medicine.

[24]  W. V. van Cappellen,et al.  Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. , 2011, Antioxidants & redox signaling.

[25]  C. Tanner,et al.  Rotenone, Paraquat, and Parkinson’s Disease , 2011, Environmental health perspectives.

[26]  A. Daiber.  Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. , 2010, Biochimica et biophysica acta.

[27]  P. Mastroberardino,et al.  Lessons from the rotenone model of Parkinson's disease. , 2010, Trends in pharmacological sciences.

[28]  K. Griendling,et al.  Nox proteins in signal transduction. , 2009, Free radical biology & medicine.

[29]  M. Ushio-Fukai.  Compartmentalization of redox signaling through NADPH oxidase-derived ROS. , 2009, Antioxidants & redox signaling.

[30]  Andrew King,et al.  Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.

[31]  J. Parga,et al.  Mechanism of 6‐hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6‐hydroxydopamine‐induced degeneration of dopaminergic neurons , 2007, Journal of neurochemistry.

[32]  D. D. Di Monte,et al.  Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation* , 2007, Journal of Biological Chemistry.

[33]  A. McCormack,et al.  Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration , 2007, Neurobiology of Disease.

[34]  C. Yabe-Nishimura,et al.  NOX1/NADPH oxidase negatively regulates nerve growth factor-induced neurite outgrowth. , 2006, Free radical biology & medicine.

[35]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[36]  E. Ogier-Denis,et al.  Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia , 2005, Neuroscience.

[37]  Keshav K. Singh,et al.  Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors , 2005, Cancer biology & therapy.

[38]  Dong-Hoon Shin,et al.  Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain , 2005, Brain Research.

[39]  M. Vila,et al.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Gerry Shaw,et al.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  F. Rey,et al.  Novel Competitive Inhibitor of NAD(P)H Oxidase Assembly Attenuates Vascular O2− and Systolic Blood Pressure in Mice , 2001, Circulation research.

[42]  Erwin G. Van Meir,et al.  Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. , 2001, Gene.

[43]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[44]  S. Estus,et al.  t NADPH Oxidase Contributes Directly to Oxidative Stress and Apoptosis in Nerve Growth Factor-Deprived Sympathetic Neurons , 2000, The Journal of Neuroscience.

[45]  J. Alegre-Abarrategui,et al.  Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers. , 2019, Methods in molecular biology.

[46]  W. Henne.  Discovery and Roles of ER-Endolysosomal Contact Sites in Disease. , 2017, Advances in experimental medicine and biology.

[47]  Xiao-Min Wang,et al.  Minimally Toxic Dose of Lipopolysaccharide and α-Synuclein Oligomer Elicit Synergistic Dopaminergic Neurodegeneration: Role and Mechanism of Microglial NOX2 Activation , 2016, Molecular Neurobiology.

[48]  M. Zimmerman,et al.  Mitochondria in Cardiovascular Physiology and Disease Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons , 2013 .

[49]  H. Lashuel,et al.  Provided for Non-commercial Research and Educational Use Only. Not for Reproduction, Distribution or Commercial Use. Author's Personal Copy Role of Post-translational Modifications in Modulating the Structure, Function and Toxicity of A-synuclein: Implications for Parkinson's Disease Pathogenesis an , 2022 .

[50]  K. Krause,et al.  The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.

[51]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.